

Voting Members Present:

K-BIOL (Interim Chair)
K-EHS
KA-ORIA
K-NAM
S-BME
D-NAM

Voting Members Absent:

A-ME (Chair)
T-ORIA
S-BIOL

Non-voting Attendees:

KS-ORIA
P-ORIA
M-OGC

The full Committee roster is posted publicly on the Georgia Tech website. All requests from the public to join a Georgia Tech IBC meeting are considered upon request. No such requests were received for this meeting.

1. A quorum being present, the meeting was called to order at 10:00 am.

2. Approval of June 11, 2026, Minutes

The June IBC minutes were sent to the committee for review. No modifications were requested.

Motion: Approve the minutes as written.

Approve: Five

Disapprove: None

Abstain: One

3. Registrations/Amendments for Discussion at Today's Meeting

TEMENOFF-R100320 (New)

Title: Evaluation of a Novel Gene Transfer Material vs Standard Lipofectamine Reagents

Funding: Georgia Research Alliance

Category: Non-Exempt, BSL-2, Section III-E-1

Discussion Leaders: S-BIOL, K-NAM

The Committee and BSO reviewed this protocol submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to evaluate the performance of a newly developed lipid capsule-based gene delivery reagent and compare it to a commercially available standard transfection reagent. The proposed use of reporter proteins and antibody isotypes indicates that this work should be classified as Non-Exempt, BSL-2, Section III-E-1. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described in this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are

suitable for the research described. The Committee requested verification that mycoplasma testing would be completed and for ORIA to confirm that the remaining reviewer was satisfied with the protocol.

Motion: Approve the protocol once the remaining reviewer confirms that it is acceptable.

Approve: Six

Disapprove: None

Abstain: None

KANE-R100041 (Renewal)

Title: Characterization of Protein Aggregation

Funding: Discretionary

Category: Non-Exempt, BSL-2, Section III-F-8 and III-E

Discussion Leaders: S-BME, K-EHS

The Committee and BSO reviewed this renewal submission and evaluated the risk assessment and proposed biocontainment plan. The goal of the proposed work is to better understand how disease-associated proteins form harmful aggregates and to develop molecules that can specifically recognize and bind to those aggregates. The proposed use of binding proteins and aggregation-prone proteins indicates that this work should be classified as Non-Exempt, BSL-2, Section III-F-8 and III-E. The Committee found that the facilities, procedures, practices, training, and expertise of personnel described in this protocol are appropriate for the proposed work. The PI has identified the potential risks involved with this research and has included plans to mitigate such risks that are suitable for the research described. The Committee had no concerns with this protocol.

Motion: Approve the protocol as written.

Approve: Six

Disapprove: None

Abstain: None

4. Other business

Protocol Form Update

- The Committee was updated on the proposed addition of an "other" category in Question 3.2 - for containment levels not covered by ABSL/BSL, to allow for applicable containment levels to be identified. The Committee agreed with the proposed form update.

Next meeting August 6, 2026